AOD-9604 Research for Obesity
An overview of research and source records on AOD-9604 in the context of obesity.
Research Summary
FDA's 2024 PCAC briefing reports that the sponsor's randomized OPTIONS study did not find statistically significant weight loss versus placebo at its 12-week primary endpoint or at 24 weeks. FDA says the detailed efficacy report was not published in medical literature. The published pooled human paper primarily reports safety observations; it is not an independent efficacy trial.
An obesity treatment effect has not been established. This summary is research context, not treatment guidance.
References
Open a reference to inspect its source record. A citation does not establish a clinical benefit.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.